Gilead Sciences Inc
GILD112.470USD
+0.180+0.16%
Market hours （ET）Quotes delayed by 15 min
140.03BMarket Cap
23.47P/E TTM
More Details of Gilead Sciences Inc Company
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.
Company Info
Ticker SymbolGILD
Company nameGilead Sciences Inc
IPO dateJan 22, 1992
Founded at1987
CEOMr. Daniel P. O'Day
Number of employees17600
Security typeOrdinary Share
Fiscal year-endJan 22
Address333 Lakeside Dr
CityFOSTER CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94404-1147
Phone16505743000
Websitehttps://www.gilead.com/
Ticker SymbolGILD
IPO dateJan 22, 1992
Founded at1987
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
89.94K
-3.23%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+6.18%
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Executive Vice President - Corporate Affairs, General Counsel
Executive Vice President - Corporate Affairs, General Counsel
25.70K
+23.67%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+14.82%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Dr. Ted W. Love, M.D.
Dr. Ted W. Love, M.D.
Independent Director
Independent Director
--
--
Mr. Javier J. Rodriguez
Mr. Javier J. Rodriguez
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
89.94K
-3.23%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+6.18%
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Executive Vice President - Corporate Affairs, General Counsel
Executive Vice President - Corporate Affairs, General Counsel
25.70K
+23.67%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+14.82%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
By BusinessUSD
Name
Revenue
Proportion
Biktarvy
3.15B
47.25%
Descovy
586.00M
8.79%
Yescarta
386.00M
5.79%
Genvoya
364.00M
5.46%
Sofosbuvir/Velpatasvir
345.00M
5.17%
Other
1.84B
27.54%
By RegionUSD
Name
Revenue
Proportion
United States
4.47B
67.02%
Europe
1.06B
15.94%
Other Locations
829.00M
12.43%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Biktarvy
3.15B
47.25%
Descovy
586.00M
8.79%
Yescarta
386.00M
5.79%
Genvoya
364.00M
5.46%
Sofosbuvir/Velpatasvir
345.00M
5.17%
Other
1.84B
27.54%
Shareholding Stats
Updated: Thu, May 15
Updated: Thu, May 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.40%
BlackRock Institutional Trust Company, N.A.
5.68%
State Street Global Advisors (US)
4.79%
Capital Research Global Investors
4.39%
Capital World Investors
4.30%
Other
71.44%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.40%
BlackRock Institutional Trust Company, N.A.
5.68%
State Street Global Advisors (US)
4.79%
Capital Research Global Investors
4.39%
Capital World Investors
4.30%
Other
71.44%
Shareholder Types
Shareholders
Proportion
Investment Advisor
52.90%
Investment Advisor/Hedge Fund
25.33%
Research Firm
2.92%
Pension Fund
2.92%
Hedge Fund
2.04%
Bank and Trust
1.84%
Sovereign Wealth Fund
1.72%
Insurance Company
0.13%
Individual Investor
0.08%
Other
10.11%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
3373
1.12B
90.10%
-7.74M
2025Q1
3442
1.12B
90.14%
-10.49M
2024Q4
3313
1.12B
90.13%
+4.63M
2024Q3
3207
1.10B
88.48%
-11.56M
2024Q2
3188
1.10B
88.24%
-14.37M
2024Q1
3196
1.10B
88.13%
-22.04M
2023Q4
3252
1.11B
88.75%
-8.79M
2023Q3
3190
1.10B
88.14%
-23.58M
2023Q2
3196
1.10B
88.02%
-11.22M
2023Q1
3195
1.09B
87.26%
-11.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
116.91M
9.4%
+1.94M
+1.69%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
70.66M
5.68%
-3.80M
-5.11%
Mar 31, 2025
State Street Global Advisors (US)
59.52M
4.79%
-858.08K
-1.42%
Mar 31, 2025
Capital Research Global Investors
54.61M
4.39%
-3.34M
-5.76%
Mar 31, 2025
Capital World Investors
53.55M
4.3%
-18.16M
-25.32%
Mar 31, 2025
Fidelity Management & Research Company LLC
51.21M
4.12%
+16.57M
+47.83%
Mar 31, 2025
Dodge & Cox
32.69M
2.63%
-252.93K
-0.77%
Mar 31, 2025
Geode Capital Management, L.L.C.
28.48M
2.29%
+190.23K
+0.67%
Mar 31, 2025
Wellington Management Company, LLP
27.36M
2.2%
-8.30M
-23.28%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
25.70M
2.07%
-130.67K
-0.51%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
VanEck Biotech ETF
13.56%
Invesco Nasdaq Biotechnology ETF
8.68%
ProShares Ultra Nasdaq Biotechnology
7.94%
iShares Biotechnology ETF
7.81%
Coastal Compass 100 ETF
5.83%
Invesco Pharmaceuticals ETF
5.41%
Invesco Biotechnology & Genome ETF
5.25%
ProShares Nasdaq-100 Dorsey Wright Momentum ETF
4.41%
USCF Dividend Income Fund
4.27%
First Trust NASDAQ Pharmaceuticals ETF
3.9%
View more
VanEck Biotech ETF
Proportion13.56%
Invesco Nasdaq Biotechnology ETF
Proportion8.68%
ProShares Ultra Nasdaq Biotechnology
Proportion7.94%
iShares Biotechnology ETF
Proportion7.81%
Coastal Compass 100 ETF
Proportion5.83%
Invesco Pharmaceuticals ETF
Proportion5.41%
Invesco Biotechnology & Genome ETF
Proportion5.25%
ProShares Nasdaq-100 Dorsey Wright Momentum ETF
Proportion4.41%
USCF Dividend Income Fund
Proportion4.27%
First Trust NASDAQ Pharmaceuticals ETF
Proportion3.9%
Dividend
A total of
18.49B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 11, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025
Mar 14, 2025
Mar 28, 2025
Mar 14, 2025
Nov 12, 2024
GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024
Dec 13, 2024
Dec 30, 2024
Dec 13, 2024
Aug 13, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024
Sep 13, 2024
Sep 27, 2024
Sep 13, 2024
Apr 26, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024
Jun 14, 2024
Jun 27, 2024
Jun 14, 2024
Feb 06, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Mar 28, 2024
Mar 14, 2024
Nov 08, 2023
GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023
Dec 15, 2023
Dec 28, 2023
Dec 14, 2023
Aug 07, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Sep 28, 2023
Sep 14, 2023
Apr 28, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jun 29, 2023
Jun 14, 2023
Feb 02, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Mar 30, 2023
Mar 14, 2023
Oct 27, 2022
GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022
Dec 15, 2022
Dec 29, 2022
Dec 14, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
